183 related articles for article (PubMed ID: 38002021)
1. Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic-Pharmacodynamic Modeling.
Jeong SH; Jang JH; Lee YB
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002021
[TBL] [Abstract][Full Text] [Related]
2. Is Gender an Important Factor in the Precision Medicine Approach to Levocetirizine?
Jeong SH; Jang JH; Lee YB
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38276516
[TBL] [Abstract][Full Text] [Related]
3. Modeling population pharmacokinetics of morniflumate in healthy Korean men: extending pharmacometrics analysis to niflumic acid, its major active metabolite.
Jeong SH; Jang JH; Lee YB
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):843-856. PubMed ID: 37515737
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
McLeay SC; Green B; Treem W; Thyssen A; Mannaert E; Kimko H
Clin Pharmacokinet; 2014 Oct; 53(10):943-57. PubMed ID: 25168707
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects.
Harada A; Ikushima I; Haranaka M; Yanagihara A; Nakayama D
Am J Cardiovasc Drugs; 2020 Jun; 20(3):249-258. PubMed ID: 31667735
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.
Sheng YC; Wang K; He YC; Yang J; Zheng QS
Eur J Clin Pharmacol; 2010 Nov; 66(11):1165-9. PubMed ID: 20838991
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole.
Bae S; Kwon J; Lee MH; Yu KS; Lee S
Drug Des Devel Ther; 2023; 17():497-506. PubMed ID: 36814893
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method.
Chen ZY; Xie HT; Zheng QS; Sun RY; Hu G
Eur J Drug Metab Pharmacokinet; 2006; 31(1):27-33. PubMed ID: 16715780
[TBL] [Abstract][Full Text] [Related]
10. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
Hayato S; Hasegawa S; Hojo S; Okawa H; Abe H; Sugisaki N; Munesue M; Horai Y; Ohnishi A
Eur J Clin Pharmacol; 2012 May; 68(5):579-88. PubMed ID: 22108775
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs.
Patel H; Desai N; Patel P; Modi N; Soni K; Patel JR; Mistry GN; Patel JD; Chawla M; Srinivas NR
Drug Dev Ind Pharm; 2019 Sep; 45(9):1459-1467. PubMed ID: 31216902
[No Abstract] [Full Text] [Related]
12. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
13. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
14. Quality by Design Applied Development of Immediate-Release Rabeprazole Sodium Dry-Coated Tablet.
Lee SH; Kim JE
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33673019
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
Robinson M; Horn J
Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of rabeprazole granules versus tablets, and the effect of food on the pharmacokinetics of rabeprazole granules in healthy adults-cross-study comparison.
Thyssen A; Solanki B; Gonzalez M; Leitz G; Treem W; Mannaert E
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):406-16. PubMed ID: 27129014
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets.
Zhang Y; Wo SK; Leng W; Gao F; Yan X; Zuo Z
J Control Release; 2022 Jun; 346():275-288. PubMed ID: 35461968
[TBL] [Abstract][Full Text] [Related]
18. Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure.
Keane WF; Swan SK; Grimes I; Humphries TJ
J Clin Pharmacol; 1999 Sep; 39(9):927-33. PubMed ID: 10471983
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
20. Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.
Thyssen A; Solanki B; Treem W
Clin Ther; 2012 Jul; 34(7):1636-45. PubMed ID: 22748970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
